ZBH news

Zimmer Biomet reported third-quarter net sales of $2.063 billion, an increase of 3.1%, despite diluted earnings per share dropping 13.8% to $1.00. The company raised its full-year guidance as innovation and commercial execution drove broad-based growth.

Zimmer Biomet reported Q2 revenue growth of 4.8% and updated full-year 2026 guidance to reflect solid performance, while also increasing its share repurchase expectations to $1 billion.

Zebra Technologies filed its 2026 Long-Term Incentive Plan for stockholder approval at the 2026 annual meeting, which would replace the 2018 plan and provide equity compensation tools to attract and retain key personnel. The plan aligns executive compensation with shareholder interests through vario…